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OBJECTIVE— A large proportion of vulvovaginal candidiasis (VVC) in diabetes is due to
non–albicans Candida species such as C. glabrata and C. tropicalis. Observational studies indicate
that diabetic patients with C. glabrata VVC respond poorly to azole drugs. We evaluated the
response to oral fluconazole and boric acid vaginal suppositories in diabetic patients with VVC.
RESEARCH DESIGN ANDMETHODS— A total of 112 consecutive diabetic patients
with VVC were block randomized to receive either single-dose oral 150-mg fluconazole or boric
acid vaginal suppositories (600 mg/day for 14 days). The primary efficacy outcome was the
mycological cure in patients with C. glabrata VVC in the two treatment arms. The secondary
outcomes were the mycological cure in C. albicans VVC, overall mycological cure irrespective of
the type of Candida species, frequencies of yeast on direct microscopy, and clinical symptoms
and signs of VVC on the 15th day of treatment. Intention-to-treat (ITT; n  111) and per-
protocol (PP; n  99) analyses were performed.
RESULTS— C. glabrata was isolated in 68 (61.3%) and C. albicans in 32 (28.8%) of 111
subjects. Patients with C. glabrata VVC showed higher mycological cure with boric acid com-
pared with fluconazole in the ITT (21 of 33, 63.6% vs. 10 of 35, 28.6%; P  0.01) and PP
analyses (21 of 29, 72.4% vs. 10 of 30, 33.3%; P 0.01). The secondary efficacy outcomes were
not significantly different in the two treatment arms in the ITT and PP analyses.
CONCLUSIONS— Diabetic women with C. glabrata VVC show higher mycological cure
with boric acid vaginal suppositories given for 14 days in comparison with single-dose oral
150-mg fluconazole.
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P atients with diabetes are at increasedrisk of developing vulvovaginal can-didiasis (VVC) (1–8). Unlike nondi-
abetic women, these patients have a
higher proportion of colonization/
infection due to non–albicans Candida
species such as C. glabrata and C. tropica-
lis (4,6–8). In contrast, C. albicans VVC is
more frequent in nondiabetic women (9).
Moreover, diabetic patients with C. gla-
brata VVC respond poorly to single oral
doses of 150 mg fluconazole (8). C. gla-
brata demonstrates intrinsically reduced
susceptibility to azole drugs (10–13).
Redondo-Lopez et al. (10) and other
investigators have reported the successful
use of vaginal boric acid suppositories in
the management of patients with C. gla-
brata (10,14,15) as well as C. albicans
VVC (16–18). In view of the higher fre-
quency of C. glabrata VVC among diabetic
women and their poor response to flucon-
azole, there is a need for a therapeutic reg-
imen that is effective against both C.
glabrata and C. albicans. To the best of our
knowledge, there is no previous study re-
porting the effect of boric acid vaginal
suppositories in diabetic women with
VVC. In the current open-label, random-
ized trial, we report the response to oral
fluconazole and boric acid vaginal sup-
positories in diabetic patients with VVC.
RESEARCH DESIGN AND
METHODS— This was a random-
ized, open-label comparison of 2 weeks’
duration between single-dose oral
150-mg fluconazole and 14 days of treat-
ment with boric acid vaginal supposito-
ries (600 mg/day) in 112 consecutive
patients with diabetes (type 2 diabetes,
n  77 and type 1 diabetes, n  35) and
VVC conducted during 2004–2006. Dia-
betes was diagnosed as per the American
Diabetes Association Expert Committee
criteria (19). Patients already on insulin or
oral hypoglycemic agents also were in-
cluded. Any patient with onset of diabetes
before age 30 years who had received con-
tinuous insulin treatment since diagnosis
was considered to have type 1 diabetes.
Subjects excluded were those who were
pregnant, sexually inactive girls, those
aged 65 years, those with renal insuffi-
ciency (serum creatinine 1.8 mg/dl),
and those on steroid therapy. Patients
who did not give consent for pelvic exam-
ination, those treated for vaginal dis-
charge during the past 3 months, and
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symptomatic patients in whom Candida
growth was not detected on fungal culture
were also excluded. A1C was measured in
all the subjects to assess their glycemic
control (normal range: 5.4–7.0%) at visit
1. The institutional ethics committee of
the All India Institute of Medical Sciences
approved the study protocol, and all the
subjects were examined after their in-
formed consent.
Diagnosis of VVC
A large number of diabetic patients were
assessed for symptoms and signs of VVC
including vaginal discharge, vulval pruri-
tus, burning sensation, vulval edema, and
vaginal congestion at visit 1 (20). Two
sterile cotton-tipped commercial swabs
were used to collect discharge from high
vagina and transported to the mycology
laboratory without delay. One of the
swabs was used to determine the presence
of yeast by direct microscopy, while the
other was used for fungal culture. The
VVC was diagnosed in the presence of
clinical signs and symptoms and growth
of Candida species on culture of the high
vaginal swab (HVS).
Detection and identification of the
yeast up to the species level was done in
the mycology laboratory of the All India
Institute of Medical Sciences as per the
standard protocols (21,22). The criteria
for laboratory diagnosis were 1) direct
demonstration of the yeast by Gram’s
staining and 2) culture on Sabouraud’s
dextrose agar supplemented with 2
mg/ml gentamicin, with and without cy-
clohexamide (0.5%). Identification of
Candida species was performed by exam-
ining colony morphology, germ tube test,
hyphal morphology, and chlamydospore
formation on cornmeal agar, triphenyl
tetrazolium reduction test, fermentation
and assimilation of different sugars, and
cycloheximide susceptibility.
Randomization and concealment
Following identification of Candida
growth on HVSs, subjects were assigned
to receive single-dose oral 150-mg flu-
conazole or boric acid vaginal supposito-
ries (600 mg/day) for 14 days in a 1:1 ratio
using a randomization list with random
permutated blocks, length of 4, at the clinic
site (visit 2). The randomization list was
generated using a Microsoft Excel spread-
sheet as described in detail (available at
http://www.childrens-mercy.org/stats/
plan/random.asp). Block randomization
was used to ensure the balance in the
number of patients in the two treatment
arms.
A statistician generated the entire ran-
domization sequence list in advance, and
allocations were sequentially numbered
from the beginning to end. A female clin-
ical investigator (D.R.) carried out genital
examinations for VVC, including an HVS
for fungal culture for all consecutive dia-
betic patients attending the endocrine
outpatients clinic and gave a serial num-
ber to all the patients examined. Follow-
ing a report of yeast growth, two
clinicians (D.R. and R.G.) assigned pa-
tients to a treatment arm, as per the serial
order of the clinical examination and ran-
domization list sequence number, in an
irreversible manner. One of these two cli-
nicians (R.G.) was not involved with clin-
ical examination. Patients were allocated
to treatment arm following reports of
yeast growth but before the results of Can-
dida species were available. The serial or-
der of the randomization list was not
disclosed to the patients until the treat-
ment was assigned.
The intake of fluconazole was super-
vised to ensure compliance. Patients re-
ceiving boric acid were instructed to
insert one boric acid–filled gelatin capsule
(600 mg) intravaginally every night for 14
uninterrupted days either by a plastic ap-
plicator or dispensed by hand as per their
preference. Two extra capsules were
given, and unused capsules were counted
on the follow-up visit to assess compli-
ance. Patients in both treatment arms
were reassessed on the 15th day of ther-
apy (visit 3). To minimize interobserver
variation, the same investigator carried
out the repeat clinical assessment at visit 3
when HVSs were taken again for demon-
stration of yeast by direct microscopy and
fungal culture. All the HVSs were of the
same color and size and sent to the myco-
logical laboratory in identical containers
labeled with a numerical identity. The
plan of block randomization, patients’
treatment assignments, the pre- and post-
nature of the specimen and clinical find-
ings were not disclosed to the mycologist
and the laboratory staff who performed
fungal culture and species identification
till the completion of the 2-year study.
Efficacy outcomes
The primary objective was to test the hy-
pothesis that diabetic patients with C. gla-
brata VVC when treated with boric acid
vaginal suppositories (600 mg/day) for 14
days show a higher mycological cure rate
in comparison with a single oral dose of
150 mg fluconazole. Mycological cure
was defined as the absence of Candida
growth on the HVS culture on the 15th
day of therapy. The primary efficacy out-
come was the mycological cure in patients
with C. glabrata VVC in the two treatment
arms. The secondary efficacy outcomes
were mycological cure in C. albicans VVC,
overall mycological cure irrespective of
the type of Candida species isolated, pres-
ence of yeast on direct microscopy, and
frequency of clinical symptoms and signs
of VVC on the 15th day in the two treat-
ment arms.
Adverse effects
Treatment-emergent adverse events were
defined as those occurring after receiving
the first dose of treatment.
Sample size and power calculations
Sample size estimation for the assessment
of primary efficacy outcome was based on
our previously published mycological
cure rate of 18.7% in diabetic patients
with C. glabrata VVC after a single oral
dose of 150 mg fluconazole therapy (8).
The sample size was calculated using a
statistical program (EPI-Info 2002; Cen-
ters for Disease Control and Prevention,
Atlanta, GA), assuming the persistence of
the above trend and three times higher
response rate (56.1%) with boric acid
therapy. Calculations revealed that 30
subjects with C. glabrata infection in each
of the two treatment arms would be re-
quired to give a study power of 80% at
95% CI. With a 54.1% prevalence rate of
C. glabrata infection, as observed in our
previous study in diabetic subjects with
VVC (8), a sample size of 112 diabetic
patients with VVC was estimated to give
us 60 subjects with C. glabrata VVC.
Statistical analysis
Both intention-to-treat (ITT) and per-
protocol (PP) analyses were performed as
efficacy analyses. Patients included in the
ITT analysis included all those who were
assigned to the two treatment arms and in
whom at least baseline HVS culture
showed Candida growth. To be included
in the PP analysis, patients also had to
comply with the assigned treatment regi-
men and follow-up as per the study
protocol on day 15 (visit 3). For determi-
nation of the primary and secondary effi-
cacy outcomes in the ITT analysis,
missing data were imputed by explicit al-
location of poor outcome in both treat-
ment arms. The differences in the mean
age, BMI, and A1C between patients in
Ray and Associates
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the two treatment arms were analyzed us-
ing Student’s t test. Logistic regression
analysis, with mycological cure as the de-
pendent variable and treatment group
and A1C as the independent variable, was
used to determine the significance of dif-
ference in the primary and secondary ef-
ficacy outcomes in the two treatment
groups. The differences in the parametric
and nonparametric indexes between sub-
jects who grew C. albicans and C. glabrata
on HVS culture were compared using a
Student’s t test and 2 test, respectively.
All P values calculated were two tailed,
and P  0.05 was considered significant.
SPSS 7.5.1 statistical package was used
for analysis.
RESULTS— Of 112 subjects random-
ized to the two treatment arms, 111 were
included in the ITT analysis and 99 were
analyzed in the PP analysis. One patient
was excluded from the ITT analysis be-
cause she fell into exclusion criteria (sex-
ually inactive, in whom a HVS was not
taken). Twelve patients were dropped for
PP analysis because of the following rea-
sons: two stopped boric acid therapy due
to vaginal burning sensation appearing on
the 7th day of therapy, two did not come
for follow-up because of diabetic foot and
pulmonary consolidation (fluconazole
arm), and eight patients were lost to fol-
low-up for unknown reasons (four in
each of the two treatment arms).
The most common species isolated in
the cohort of 111 patients included in the
ITT analysis was C. glabrata (n  68,
61.3%), followed by C. albicans (n  32,
28.8%) and C. tropicalis (n  4, 3.6%).
The baseline demographic and clinical
characteristics, including the proportion
of patients with type 1 and type 2 diabe-
tes, frequencies of C. glabrata and C. albi-
cans species isolated on HVS culture,
number of postmenopausal women, and
those using commercially available pro-
tective sanitary napkins, were comparable
in both the treatment arms in the ITT and
PP analyses groups (Table 1). Only two
women were on oral contraceptive pills
(one in each of the two treatment arm).
The mean A1C value at baseline was
lower in the boric acid treatment arm than
in the fluconozaole arm in the ITT as well
as in the PP analyses group. The primary
and secondary efficacy outcomes were,
therefore, adjusted for A1C at baseline
(Table 2).
The mycological cure rate in patients
with C. glabrata VVC was significantly
higher in the boric acid treatment arm
compared with the fluconazole arm in
both the ITT and PP analyses (P values
0.01 for both after adjustment for baseline
A1C). The odds in favor of mycological
cure with boric acid vaginal suppositories
in diabetic patients with C. glabrata VVC
was 4.0 (95% CI 1.4–11.6). The good-
ness of fit of the logistic regression model
was assessed by Nagelkerke R2. Although
the Nagelkerke R2 value for primary out-
come was only 15.3%, the model should
not be interpreted as inadequate (23). No
significant difference in mycological cure
was observed in the two treatment arms in
subjects with C. albicans VVC. The overall
mycological cure on the 15th day, when
analyzed irrespective of the type of Can-
dida species isolated at baseline HVS cul-
ture, tended to be higher in those
receiving boric acid in the ITT (P 0.07)
and PP (P 0.06) analyses. The improve-
ment in vaginal pruritus, discharge, and
other clinical signs and symptoms was
comparable in the two treatment arms in
the ITT or PP analyses.
The duration of different symptoms
and signs related to VVC, yeast positivity
on direct microscopy, and mean A1C val-
ues were comparable in diabetic subjects
who grew C. albicans and C. glabrata in
the ITT and PP analyses groups. The
mean A1C tended to be higher in subjects
who continued to grow Candida on repeat
HVS culture compared with those who
did not grow Candida in the ITT (9.3 
2.0% vs. 8.6  2.1%; P  0.11) and PP
groups (9.5 2.2% vs. 8.6 2.1%; P
0.06).
Adverse effects
Two of the patients in the boric acid treat-
ment arm who stopped the treatment due
to vaginal burning sensation were consid-
ered to demonstrate the adverse effect, as
this improved after stopping the drug.
CONCLUSIONS— The 59.9% prev-
alence of C. glabrata infection observed in
the current study confirms the findings of
our earlier studies that non-albicans VVC
is frequent in diabetic women (4,8). de
Leon et al. (6) observed the 54% vaginal
carriage rate of C. glabrata in type 2 dia-
betes. The comparable frequency of clin-
ical symptoms and signs between diabetic
Table 1—Baseline clinical characteristics, symptoms, and signs and type of Candida species in the ITT and PP groups
Parameters
ITT analysis
P value
PP analysis
P valueFluconazole Boric acid Fluconazole Boric acid
n 55 56 49 50
Age (years) 40.2  10.7 41.2  11.3 0.63 40.2  9.8 40.8  11.5 0.78
BMI (kg/m2) 24.4  5.4 24.9  4.5 0.64 24.6  5.6 24.7  4.7 0.88
A1C (%) 9.36  2.5 8.5  1.6 0.04 9.35  2.8 8.5  1.7 0.05
Postmenopausal 21 (38.1) 17 (30.3) 0.50 19 (38.8) 14 (28.0) 0.35
Use of commercial sanitary napkins during
menstruation
14 (41.2) 22 (56.4) 0.28 13 (43.3) 22 (61.1) 0.23
VVC symptoms for 1 month 50 (90.9) 47 (83.9) 0.41 44 (89.8) 41 (82.0) 0.40
Vulval pruritus 45 (81.8) 41 (73.2) 0.39 40 (81.6) 35 (70.0) 0.26
Vulval edema 5 (9.0) 13 (23.2) 0.08 5 (10.2) 9 (18.0) 0.40
Vaginal congestion 39 (70.9) 43 (76.7) 0.62 33 (67.3) 37 (74.0) 0.61
Direct microscopy positivity 35 (63.6) 30 (53.5) 0.37 29 (59.2) 24 (48.0) 0.36
C. glabrata 35 (63.6) 33 (58.9) 0.75 30 (61.2) 29 (58.0) 0.90
C. albicans 14 (25.4) 18 (32.1) 0.95 13 (26.5) 16 (32.0) 0.92
Other Candida species 6 (10.9) 5 (8.9) 0.97 6 (12.2) 5 (10.0) 0.97
Data are means SD for age, BMI, and A1C and n (%) for other indices in the two treatment arms in ITT and PP groups. P values test differences in the means or
proportions observed in the two treatment arms.
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women with C. glabrata or C. albicans in-
fection is similar to that reported by Gei-
ger et al. (24) in nondiabetic women.
Increased prevalence of C. glabrata
infection in diabetic women has clinical
relevance because poor therapeutic re-
sponse and innate resistance to azoles has
been reported for C. glabrata VVC in non-
diabetic women (10–13). Similar infor-
mation is lacking in diabetic subjects, as
they are often excluded in antifungal effi-
cacy studies (8,10,25–27). Poor mycolog-
ical cure in diabetic women with C.
glabrata VVC to single-dose oral 150-mg
fluconazole, observed in the current
study, is in accordance with our earlier
case-control study (8). Mechanisms im-
plicated for resistance of C. glabrata to flu-
conazole include increased fungal
ergosterol synthesis and up to eightfold
higher expression of azole efflux pump
protein coded by CgCDR1 transporter
genes (26,28). Diabetic patients with
VVC also respond poorly to itraconazole
and ketoconazole (29,30)
In the current study, the higher my-
cologoical cure (72.4%) to boric acid
therapy in diabetics with C. glabrata VVC
is similar to that reported in nondiabetic
individuals (10,14–18). In 1974, Swate
and Weed (16) first reported boric acid to
be a “safe, effective and inexpensive form
of therapy” for VVC. Sobel and Chaim
(14) reported clinical improvement in
81% and mycological cure in 77% of non-
diabetic patients with symptomatic C. gla-
brata/Torulopsis vaginitis treated with
vaginal boric acid. There are also reports
of better therapeutic response to boric
acid compared with topical nystatin and
miconazole in nondiabetic women with
C. albicans VVC (17,18). Otero et al. (31)
have reported a greater in vitro suscepti-
bility of C. albicans to boric acid compared
with C. glabrata.
Boric acid or boracic [B(OH)3] is a
weak acid, and its mode of antifungal ac-
tion is not clear. Shiohara and Tasker (15)
proposed that its acidic properties lead to
disruption of the fungal cell wall. The pH
of boric acid–Sabourauds’s broth (5.0–
5.09) required for in vitro inhibition of C.
albicans growth has been reported to be
similar to the vaginal pH in untreated
Candida vaginitis, indicating that the ef-
fect of boric acid is not specific to its acidic
properties (17). Alkaline compound (i.e.,
Na2B4O3 [borax]) also has antiseptic
properties (32). The doses of the boric
acid used to treat VVC have ranged from
600 mg daily for 7 days (16) to twice daily
for 14 days (18). We used 600 mg boric
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acid daily for 14 days because90% my-
cological cure has been reported with this
schedule in nondiabetic patients with
symptomatic C. albicans (17) or C. gla-
brata VVC (14).
Boric acid therapy (600 mg/day for
14 days) has been found to be safe
(14,17), except for local burning sensa-
tion and vestibular erythema in occa-
sional patients (14,17,18). Two of our
patients also reported this side effect.
Improvement in clinical features of VVC
was comparable in two treatment arms.
However, we cannot exclude an ele-
ment of bias in the analysis of this
secondary outcome, as the same inves-
tigator carried out the clinical examina-
tion following treatment.
In our previous studies, poor glyce-
mic control was linked with Candida
growth (4) but was unrelated to the type
of species isolated or response to the flu-
conazole therapy (8). In the current
study, there was a trend of higher mean
A1C levels in those showing persistence
of Candida growth following either of the
two therapies. The cause of increased C.
glabrata isolation in diabetic women is not
clear but may involve frequent use of an-
tifungal drugs leading to its reduced sus-
ceptibility to azoles (33) and consequent
polarization/homing in diabetic women.
Feng et al. (34) reported lesser suscepti-
bility of C. glabrata in comparison with C.
albicans to -defensins, natural cationic
antimicrobial/antifungal peptides ex-
pressed in human epithelia. In diabetic
milieu, -defensins expression is reduced
(35). Reduced expression of defensins in
association with resistance of C. glabrata
to fungicidal activity of drugs like flucon-
azole may also explain the high preva-
lence of C. glabrata VVC in diabetic
women.
One of the relevant findings in this
study is the importance of species identi-
fication of Candida isolates for proper
management of VVC in diabetic women.
It is emphasized that conventional inex-
pensive testing procedures, though time
consuming, are good enough to identify
Candida up to species level and would
help in the management of diabetic
women with VVC. As an alternative, boric
acid therapy could be considered as the
frontline therapy for treating VVC in dia-
betic women because it is effective against
both C. albicans and C. glabrata compared
with fluconazole, which is effective
against C. albicans only.
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